Bussey HJR (1975) Familial polyposis coli: family studies, histopathology, differential diagnosis and results of treatment. John Hopkins University, Baltimore

Google Scholar 

Latchford A, Clark S (2023) Is there a role for endoscopic management of the large bowel in Familial adenomatous polyposis?Endoscopy. 55:353–354

Hopper AD (2022) Role of endoscopy in patients with Familial adenomatous polyposis. Frontline Gastroenterol 13(e1):e72–e79

Article  PubMed  PubMed Central  Google Scholar 

Cwaliński J, Zasada W, Cholerzyńska H, Andrzejewska W, Michalak H, Banasiewicz T, Paszkowski J (2024) Endoscopic surveillance after (Procto)Colectomy with Gastrointestinal reconstruction in patients with Familial adenomatous polyposis (FAP)—Principles, goals and practical aspects based on 12 years of observation. Life 14(8):1000

Article  PubMed  PubMed Central  Google Scholar 

Nugent KP, Spigelman AD, Phillips RK (1993) Life expectancy after colectomy and ileorectal anastomosis for Familial adenomatous polyposis. Dis Colon Rectum 36(11):1059–1062

Article  CAS  PubMed  Google Scholar 

Ishikawa H, Yamada M, Sato Y, Tanaka S, Akiko C, Tajika M, Doyama H, Takayama T, Ohda Y, Horimatsu T, Sano Y, Tanakaya K, Ikematsu H, Saida Y, Ishida H, Takeuchi Y, Kashida H, Kiriyama S, Hori S, Lee K, Tashiro J, Kobayashi N, Nakajima T, Suzuki S, Mutoh M (2022) Intensive endoscopic resection for downstaging of polyp burden in patients with Familial adenomatous polyposis (J-FAPP study III): a multicenter prospective interventional study. Endoscopy 55:344–352

PubMed  PubMed Central  Google Scholar 

Falsetti I, Palmini G, Iantomasi T, Brandi ML, Tonelli F (2024) Mechanisms of action of phytoestrogens and their role in Familial adenomatous polyposis. Pharmaceutics 16(5):640

Article  CAS  PubMed  PubMed Central  Google Scholar 

Aelvoet AS, Pellisé M, Bastiaansen BAJ, van Leerdam ME, Jover R, Balaguer F, Kaminski MF, Karstensen JG, Saurin JC, Hompes R, Bossuyt PMM, Ricciardiello L, Latchford A, Dekker E, European FAP (2023) Personalized endoscopic surveillance and intervention protocols for patients with Familial adenomatous polyposis: the European FAP consortium strategy. Endosc Int Open 11(4):E386–E393

Article  PubMed  PubMed Central  Google Scholar 

Yang J, Gurudu SR, Koptiuch C, Agrawal D, Buxbaum JL, Abbas Fehmi SM, Fishman DS, Khashab MA, Jamil LH, Jue TL, Law JK, Lee JK, Naveed M, Qumseya BJ, Sawhney MS, Thosani N, Wani SB, Samadder NJ (2020) American society for Gastrointestinal endoscopy guideline on the role of endoscopy in Familial adenomatous polyposis syndromes. Gastrointest Endosc 91(5):963–982e2

Article  PubMed  Google Scholar 

Van Leerdam ME, Roos VH, van Hooft JE et al (2019) Endoscopic management of polyposis syndromes: European society of Gastrointestinal endoscopy (ESGE) guideline. Endoscopy 51:877–895

Article  PubMed  Google Scholar 

Anele CC, Martin I, McGinty Duggan PM, Chauhan J, Clark SK, Faiz OD, Latchford AR (2022) Attenuated Familial adenomatous polyposis: A phenotypic diagnosis but obsolete term?? Dis Colon Rectum 65(4):529–535

Article  PubMed  Google Scholar 

Church J, Burke C, McGannon E et al (2003) Risk of rectal cancer in patients after colectomy and ileorectal anastomosis for Familial adenomatous polyposis: a function of available surgical options. Dis Colon Rectum 46:1175–1181

Article  PubMed  Google Scholar 

Anele CC, Xiang J, Martin I, Hawkins M, Man R, Clark SK, Faiz OD, Latchford A (2022) Regular endoscopic surveillance and polypectomy is effective in managing rectal adenoma progression following colectomy and ileorectal anastomosis in patients with Familial adenomatous polyposis. Colorectal Dis 24(3):277–283

Article  PubMed  Google Scholar 

Bouchiba H, Aelvoet AS, Pellisé M, Bastiaansen BAJ, van Leerdam ME, Langers AMJ, Balaguer F, Miedema TN, Anele CC, Daca-Alvarez M, Bossuyt PMM, Ricciardiello L, Jover R, Hompes R, Karstensen JG, Latchford A, Dekker E, European FAP, Consortium (2024) Risk of cancer and reoperation after ileorectal anastomosis and ileal pouch-anal anastomosis in Familial adenomatous polyposis. Am J Gastroenterol. Dec 31

Ryu HS, Yu CS, Kim YI, Lee JL, Kim CW, Yoon YS, Park IJ, Lim SB, Kim JC (2022) Cumulative incidence and risk factors for pouch adenomas associated with Familial adenomatous polyposis following restorative proctocolectomy. World J Gastroenterol 28(30):4152–4162

Article  PubMed  PubMed Central  Google Scholar 

Chika N, Mori Y, Suzuki O, Ishii T, Sugino A, Ishikawa H, Chiyonobu N, Ito T, Tanabe N, Hatano S, Ishiguro T, Matsuyama T, Kumagai Y, Inokuma S, Ishida H (2024) [Development of Cancer of the remnant colorectal segment after Ileal-Pouch anal anastomosis/ileorectal anastomosis in patients with Familial adenomatous polyposis]. Gan Kagaku Ryoho 51(3):336–339

Google Scholar 

Sriranganathan D, Vinci D, Pellino G, Segal JP (2022) Ileoanal pouch cancers in ulcerative colitis and Familial adenomatous polyposis: A systematic review and meta-analysis. Dig Liver Dis 54(10):1328–1334

Article  CAS  PubMed  Google Scholar 

Friederich P, de Jong AE, Mathus- Vliegen LM et al (2008) Risk of developing adenomas and carcinomas in the ileal pouch in patients with Familial adenomatous polyposis. Clin Gastroenterol Hepatol 6:1237–1242

Article  PubMed  Google Scholar 

Von Roon AC, Will OCC, Man RF et al (2011) Mucosectomy with handsewn anastomosis reduces the risk of adenoma formation in the anorectal segment after restorative proctocolectomy for Familial adenomatous polyposis. Ann Surg 253:314–317

Article  Google Scholar 

Boostrom SY, Mathis KL, Pendlimari R et al (2013) Risk of neoplastic change in ileal pouches in Familial adenomatous polyposis. J Gastrointest Surg 17:1804–1808

Article  PubMed  Google Scholar 

Gilad O, Tulchinsky H, Kariv R (2023) Surveillance and management of pouch neoplasia in Familial adenomatous polyposis: A systematic review. Diseases of the Colon &Rectum, 67, S82 - S90.

Matsumoto T, Nakamura S, Esaki M et al (2006) Effect of the non-steroidal anti-inflammatory drug Sulindac on colorectal adenomas of uncolectomized Familial adenomatous polyposis. J Gastroenterol Hepatol 21(1 Pt 2):251–257

Article  CAS  PubMed  Google Scholar 

Cruz-Correa M, Hylind LM, Romans KE et al (2002) Long-term treatment with Sulindac in Familial adenomatous polyposis: a prospective cohort study. Gastroenterology 122:641–645

Article  CAS  PubMed  Google Scholar 

Neuhann TM, Haub K, Steinke-Lange V et al (2022) Long-term chemoprevention in patients with adenomatous polyposis coli: an observational study. Fam Cancer 21:463–472

Article  CAS  PubMed  Google Scholar 

Kim KY, Jeon SW, Park JG et al (2014) Regression of colonic adenomas after treatment with Sulindac in Familial adenomatous polyposis: a case with a 2-year follow-up without a prophylactic colectomy. Ann Coloproctol 30:201–204

Article  PubMed  PubMed Central  Google Scholar 

Winde G, Schmid KW, Schlegel W et al (1995) Complete reversion and prevention of rectal adenomas in colectomized patients with Familial adenomatous polyposis by rectal low-dose Sulindac maintenance treatment. Advantages of a low-dose nonsteroidal anti-inflammatory drug regimen in reversing adenomas exceeding 33 months. Dis Colon Rectum 38:813–830

Article  CAS  PubMed  Google Scholar 

Giardiello FM, Hamilton SR, Krush AJ et al (1993) Treatment of colonic and rectal adenomas with Sulindac in Familial adenomatous polyposis. N Engl J Med 328:1313–1316

Article  CAS  PubMed  Google Scholar 

Labayle D, Fischer D, Vielh P et al (1991) Sulindac causes regression of rectal polyps in Familial adenomatous polyposis. Gastroenterology 101:635–639

Article  CAS  PubMed  Google Scholar 

Nugent KP, Farmer KC, Spigelman AD et al (1993) Randomized controlled trial of the effect of Sulindac on duodenal and rectal polyposis and cell proliferation in patients with Familial adenomatous polyposis. Br J Surg 80:1618–1619

Article  CAS  PubMed  Google Scholar 

Giardiello FM, Yang VW, Hylind LM et al (2002) Primary chemoprevention of Familial adenomatous polyposis with Sulindac. N Engl J Med 346:1054–1059

Article  CAS  PubMed  PubMed Central  Google Scholar 

van Stolk R, Stoner G, Hayton WL et al (2000) Phase I trial of exisulind (sulindac sulfone, FGN-1) as a chemopreventive agent in patients with Familial adenomatous polyposis. Clin Cancer Res 6:78–89

PubMed  Google Scholar 

Samadder NJ, Foster N, McMurray RP et al (2023) Phase II trial of weekly erlotinib dosing to reduce duodenal polyp burden associated with Familial adenomatous polyposis. Gut 72:256–263

Article  CAS  PubMed  Google Scholar 

Samadder NJ, Neklason DW, Boucher KM et al (2016) Effect of Sulindac and erlotinib vs placebo on duodenal neoplasia in Familial adenomatous polyposis: a randomized clinical trial. JAMA 315:1266–1275

Article  CAS  PubMed  PubMed Central  Google Scholar 

Samadder NJ, Kuwada SK, Boucher KM et al (2018) Association of Sulindac and erlotinib vs placebo with colorectal neoplasia in Familial adenomatous polyposis: secondary analysis of a randomized clinical trial. JAMA Oncol 4:671–677

Article  PubMed